Abstract
New biomarkers are currently under development for acute kidney injury and chronic kidney disease. Panels of validated biomarkers are most likely to be required to obtain information that will help in delineating acute versus chronic disease, the pathogenetic nature of the process, the severity, and the capacity for reversibility. Glycoprotein non-metastatic melanoma protein-b, a protein associated with regulation of inflammation and autophagy, is in an intermediate stage of development as a kidney injury biomarker.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.